Development of cisplatin / caffeine combined chemotherapy for hepatocellular carcinoma.

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K08102
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Medical pharmacy
• Research Institution: Daiichi University, College of Pharmaceutical Sciences (2017); University of Miyazaki (2015-2016)
• Principal Investigator: Kazuhiko Arimori 第一薬科大学, 薬学部, 教授 (70253739)
• Co-Investigator(Kenkyū-buntansha): 青山 隆夫 東京理科大学, 薬学部薬学科, 教授 (60262028) ; 河野 洋平 東京理科大学, 薬学部薬学科, 助教 (80779025)
• Research Collaborator: OKUMURA MANABU
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: カフェイン / シスプラチン / 肝細胞癌

Outline of Final Research Achievements

Caffeine inhibits the proliferation of HCC cells by suppressing cell cycle progression without causing cell death. In combination therapy with caffeine and cisplatin, caffeine inhibits the ATM pathway activated by cisplatin, and the process of DNA repair is interfered with. Caffeine also inhibits the cisplatin-activated Akt pathway, and inhibits the functional molecules suppressing mitochondria-dependent cell death. These two functions of caffeine will likely enhance the cell death effect caused by cisplatin, and the interaction of caffeine with cisplatin would be primarily through the pharmacodynamic mechanism. However, HepG2 showed resistance to the enhancer action of caffeine. It will be necessary to investigate the mechanism of resistance to the action of caffeine in the future.

Free Research Field

がん化学療法